Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4225 Executive Square, Suite - 600 SAN DIEGO CA 92037 |
Tel: | N/A |
Website: | https://zurabio.com |
IR: | See website |
Key People | ||
Robert Lisicki Chief Executive Officer, Director | Verender S. Badial Interim Chief Financial Officer | Theresa Lowry Chief Human Resource Officer |
Gary Whale Chief Technology Officer | Michael Howell Chief Scientific Officer, Head of Translational Medicine | Kiran Nistala Chief Medical Officer, Head of Development | Kim Davis Chief Legal Officer and Secretary |
Business Overview |
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. |
Financial Overview |
For the three months ended 31 March 2024, Zura Bio Ltd revenues was not reported. Net loss applicable to common stockholders decreased 93% to $730K. Lower net loss reflects Stock-based Compensation in R&D decrease of 80% to $433K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.76 to -$0.02. |
Employees: | 14 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $175.52M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$63.30M as of Mar 31, 2024 |
Net annual income (TTM): | -$60.18M as of Mar 31, 2024 |
Free cash flow (TTM): | -$24.04M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 63,683,806 as of May 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |